logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hypertensive Disease

    FiltersReset Filters
    8 results

    • edarbi

      (Azilsartan kamedoxomil)
      Azurity Pharmaceuticals, Inc.
      Usage: Edarbi is indicated for treating hypertension in adults to lower blood pressure, thereby reducing the risk of cardiovascular events such as strokes and myocardial infarctions. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.

    • edarbyclor

      (Azilsartan kamedoxomil and chlorthalidone)
      Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
      Usage: Edarbyclor is indicated for treating hypertension to lower blood pressure, particularly in patients not adequately controlled on monotherapy. It may also serve as initial therapy for those needing multiple drugs to reach blood pressure goals, reducing the risk of cardiovascular events like strokes and heart attacks.

    • inderal

      (propranolol hydrochloride)
      ANI Pharmaceuticals, Inc.
      Usage: Inderal LA is indicated for managing hypertension (alone or with other agents), reducing angina frequency, prophylaxis of migraine headaches, and improving symptoms in patients with hypertrophic subaortic stenosis. It is not recommended for hypertensive emergencies or for treating acute migraine attacks.

    • katerzia

      (Amlodipine)
      Azurity Pharmaceuticals, Inc.
      Usage: KATERZIA is indicated for treating hypertension in adults and children (6 years and older) to reduce blood pressure and cardiovascular risks. It is also used for chronic stable angina, vasospastic angina, and to lower hospitalization risks in patients with confirmed coronary artery disease.

    • labetalol hydrochloride

      (Labetalol Hydrochloride)
      Advagen Pharma Ltd
      Usage: Labetalol hydrochloride tablets USP are indicated for managing hypertension, and can be used alone or with other antihypertensive agents, particularly thiazide and loop diuretics.

    • norliqva

      (amlodipine)
      CMP Pharma, Inc.
      Usage: NORLIQVA® is indicated for treating hypertension in adults and children ages 6 and older, reducing cardiovascular event risk. It also treats chronic stable angina, vasospastic angina, and helps patients with angiographically documented coronary artery disease to lower hospitalization and revascularization risks. It can be used alone or with other agents.

    • qbrelis

      (lisinopril)
      Azurity Pharmaceuticals, Inc.
      Usage: QBRELIS is indicated for treating hypertension in patients aged 6 years and older, reducing the risk of cardiovascular events. It is also used to alleviate symptoms of systolic heart failure and decrease mortality in hemodynamically stable patients after an acute myocardial infarction.

    • tribenzor

      (olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide)
      Cosette Pharmaceuticals, Inc.
      Usage: Tribenzor is indicated for treating hypertension, either alone or with other antihypertensive agents, to lower blood pressure. This reduces the risk of cardiovascular events, such as strokes and myocardial infarctions. It is not intended for initial hypertension therapy and should be part of comprehensive cardiovascular risk management.